Volume 47 | Number 2 | April 2012

Abstract List

Jennifer Prah Ruger, Marek Chawarski, Mahmud Mazlan, Craig Luekens, Nora Ng, Richard Schottenfeld


Develop and apply new costing methodologies to estimate costs of opioid dependence treatment in countries worldwide.

Data Sources/Study Setting

Micro‐costing methodology developed and data collected during randomized controlled trial () involving 126 patients (uly 2003–ay 2005) in alaysia. Gross‐costing methodology developed to estimate costs of treatment replication in 32 countries with data collected from publicly available sources.

Study Design

Fixed, variable, and societal cost components of alaysian micro‐costed and analytical framework created and employed for gross‐costing in 32 countries selected by three criteria relative to alaysia: major heroin problem, geographic proximity, and comparable gross domestic product (GDP) per capita.

Principal Findings

Medication, and urine and blood testing accounted for the greatest percentage of total costs for both naltrexone (29–53 percent) and buprenorphine (33–72 percent) interventions. In 13 countries, buprenorphine treatment could be provided for under $2,000 per patient. For all countries except nited ingdom and ingapore, incremental costs per person were below $1,000 when comparing buprenorphine to naltrexone. An estimated 100 percent of opiate users in ambodia and ao eople's emocratic epublic could be treated for $8 and $30 million, respectively.


Buprenorphine treatment can be provided at low cost in countries across the world. This study's new costing methodologies provide tools for health systems worldwide to determine the feasibility and cost of similar interventions.